Top Markets
#1 ROLL ROLL +34.32%
#2 Lisk Lisk +33.40%
#3 Derive Derive +25.64%
#4 Cortex Cortex +20.33%
#5 MarsCoin MarsCoin +18.71%
#6 Synapse Synapse +18.60%
#7 Asteroid Shiba Asteroid Shiba +17.83%
#8 龙虾 (Lobster) 龙虾 (Lobster) +16.78%
#9 AUKI AUKI +14.66%
#10 IOST IOST +13.09%
Coin of the day
ROLL ROLL
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Rang in aandelen #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Aandeelprijs
$1,133.97
Laatst gesynchroniseerd: 2026-09-15
Marktkapitalisatie
$1.068T
Verandering (1 dag)
-0.39%
Verandering (1 jaar)
48.29%
Land
US
Handel Eli Lilly and Company (LLY)

Categorie

Healthcare
P/S-ratio voor Eli Lilly and Company (LLY)
P/S-ratio op September 2026 TTM: 13.45
Volgens de meest recente financiële rapporten en aandelenkoers van Eli Lilly and Company is de huidige P/S-ratio (TTM) 13.45. Eind 2024 had het bedrijf een P/S-ratio van 15.44.
P/S-ratiohistoriek voor Eli Lilly and Company van 2000 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 13.45 -9.19%
2025 14.81 -4.08%
2024 15.44 0.47%
2023 15.36 26.14%
2022 12.18 30.93%
2021 9.30 41.33%
2020 6.58 16.73%
2019 5.64 1.90%
2018 5.53 24.39%
2017 4.45 16.60%
2016 3.82 -18.23%
2015 4.67 19.45%
2014 3.91 58.51%
2013 2.46 -1.49%
2012 2.50 31.23%
2011 1.91 13.53%
2010 1.68 -6.52%
2009 1.80 -16.98%
2008 2.16 -30.75%
2007 3.12 -13.42%
2006 3.61 -14.14%
2005 4.20 -5.31%
2004 4.44 -26.20%
2003 6.01 -2.75%
2002 6.18 -15.65%
2001 7.33 -20.80%
2000 9.26 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.55 -51.27%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.18 -46.61%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 -65.36%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
5.39 -59.94%
US
Novartis AG Novartis AG
Novartis AG
NOVN.SW
5.52 -58.95%
CH